TerminatedPhase 2

Effectiveness of CRD-740 in Heart Failure

Stopped: Part A of the study was successfully concluded. Part B of the study was not conducted in favor of redesigned new studies.

United States60 participantsStarted 2022-05-26

Plain-language summary

This is a study evaluating the effectiveness of CRD-740 in patients with either Heart Failure with Reduced Ejection Fraction (HFrEF) or Heart Failure with Preserved Ejection Fraction (HFpEF) after 12 weeks of treatment. The primary objective in Part A is to assess the effect of CRD-740 compared to placebo in plasma cGMP at Week 4 in HFrEF. Part B of the study was not conducted in favor of redesigned new studies.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Males or Females ≥18 years of age, at screening.
✓. Diagnosis of clinical heart failure syndrome, New York Heart Association functional class II - III for at least 6 months prior to screening
✓. For Part A:

What they're measuring

Part A: The Mean Change From Baseline (Day 1) in Plasma cGMP at Week 4.

Timeframe: Baseline to Week 4

Trial details

NCT IDNCT05409183

SponsorCardurion Pharmaceuticals, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-05-02

Results submitted2024-08-22

View on ClinicalTrials.gov More Heart Failure trials